04-26-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas C. Boone et al.

Serial No.: 10/666,480

Group Art Unit No.: 1654

Filed: September 18, 2003

Examiner: Not Yet Assigned

For: Peptides and Related Molecules that Modulate Nerve Growth Factor Activity

Docket No.: A-827

NOTIFICATION OF ERROR IN SPELLING OF INVENTOR'S NAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A typographical error was made in one of the inventor's names on the above-referenced application. Kenneth D. Wild properly executed the Oath and Declaration, however, the typewritten name was incorrectly spelled Kenneth "C." Wild. Pursuant to MPEP 605.04(b), please note the change on the original Oath and Declaration in the Patent Office file and forward the correction to OIPE for revision of the records. Applicant's request that OIPE issue a corrected filing receipt to confirm the change. A copy of the initial filing receipt is attached.

Respectfully submitted,

Robert L. Sharp
Attorney for Applicant(s)
Registration No.:45,609
Phone: (805) 447-5992
Date: April 23, 2004

Please send all future correspondence to:
U.S. Patent Operations/ RLS
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EV351338609US

Date of Deposit: April 23, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

SL. ST. ANDREW
Printed Name

Signature

$9v$ ———————> RLS

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/666,480	09/18/2003	1654	4960	A-827	9	163	14

CONFIRMATION NO. 2075

21069
AMGEN INCORPORATED
MAIL STOP 27-4-A
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320-1799

RECEIVED
MAR 19 2004
PATENT OPERATIONS
AMGEN

FILING RECEIPT

DC000000012104866

Date Mailed: 03/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

> Thomas C. Boone, Newbury Park, CA;
> Kenneth C. Wild, Simi Valley, CA;
> Karen C. Sitney, Studio City, CA;
> Hosung Min, Newbury Park, CA;
> Bruce Kimmel, San Diego, CA;

-- Kenneth D. Wild

Domestic Priority data as claimed by applicant

> This appln claims benefit of 60/412,524 09/19/2002

Foreign Applications

If Required, Foreign Filing License Granted: 03/15/2004

Projected Publication Date: 06/24/2004

Non-Publication Request: No

Early Publication Request: No

Title

Peptides and related molecules that modulate nerve growth factor activity ✓

Preliminary Class
514

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).